Evidence map›Paper›PMID 38378836›Full record

ArticleTranslational psychiatry2024

Multi-level profiling of the Fmr1 KO rat unveils altered behavioral traits along with aberrant glutamatergic function.

George Ntoulas, Charalampos Brakatselos, Gerasimos Nakas, Michail-Zois Asprogerakas, Foteini Delis, Leonidas J Leontiadis, George Trompoukis, Costas Papatheodoropoulos, Dimitrios Gkikas, Dimitrios Valakos and 4 more

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

George NtoulasDepartment of Pharmacology, Faculty of Medicine, School of Health Sciences University of Ioannina, Ioannina, Greece.ORCID 0009-0007-9389-6115
Charalampos BrakatselosDepartment of Pharmacology, Faculty of Medicine, School of Health Sciences University of Ioannina, Ioannina, Greece.
Gerasimos NakasDepartment of Pharmacology, Faculty of Medicine, School of Health Sciences University of Ioannina, Ioannina, Greece.
Michail-Zois AsprogerakasDepartment of Pharmacology, Faculty of Medicine, School of Health Sciences University of Ioannina, Ioannina, Greece.
Foteini DelisDepartment of Pharmacology, Faculty of Medicine, School of Health Sciences University of Ioannina, Ioannina, Greece.
Leonidas J LeontiadisLaboratory of Neurophysiology, Department of Medicine, University of Patras, Rion, Greece.
George TrompoukisLaboratory of Neurophysiology, Department of Medicine, University of Patras, Rion, Greece.
Costas PapatheodoropoulosLaboratory of Neurophysiology, Department of Medicine, University of Patras, Rion, Greece.
Dimitrios GkikasCenter of Basic Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Dimitrios ValakosCenter of Basic Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Giannis VatsellasCenter of Basic Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.ORCID 0000-0002-1631-1060
Panagiotis K PolitisCenter of Basic Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Alexia PolissidisDepartment of Pharmacology, Faculty of Medicine, School of Health Sciences University of Ioannina, Ioannina, Greece.
Katerina AntoniouDepartment of Pharmacology, Faculty of Medicine, School of Health Sciences University of Ioannina, Ioannina, Greece. kantoniou@uoi.gr.ORCID 0000-0002-2876-207X
University of Ioannina · GRBiomedical Research Foundation of the Academy of Athens · GRUniversity of Patras · GR

Funding

General Secretariat for Research and Technology (GSRT) T2EDK-02075
6 · The paper itself

Abstract

Fragile X syndrome (FXS) is the most common cause of inherited intellectual disabilities and the most prevalent monogenic cause of autism. Although the knockout (KO) of the Fmr1 gene homolog in mice is primarily used for elucidating the neurobiological substrate of FXS, there is limited association of the experimental data with the pathophysiological condition in humans. The use of Fmr1 KO rats offers additional translational validity in this regard. Therefore, we employed a multi-level approach to study the behavioral profile and the glutamatergic and GABAergic neurotransmission status in pathophysiology-associated brain structures of Fmr1 KO rats, including the recordings of evoked and spontaneous field potentials from hippocampal slices, paralleled with next-generation RNA sequencing (RNA-seq). We found that these rats exhibit hyperactivity and cognitive deficits, along with characteristic bidirectional glutamatergic and GABAergic alterations in the prefrontal cortex and the hippocampus. These results are coupled to affected excitability and local inhibitory processes in the hippocampus, along with a specific transcriptional profile, highlighting dysregulated hippocampal network activity in KO rats. Overall, our data provide novel insights concerning the biobehavioral profile of FmR1 KO rats and translationally upscales our understanding on pathophysiology and symptomatology of FXS syndrome.

Indexed as

Cognition DisordersCognitive DysfunctionFragile X SyndromeAnimalsBrainDisease Models, AnimalFragile X Messenger Ribonucleoprotein 1HippocampusHumansMiceMice, KnockoutRatsFmr1 protein, mouseFmr1 protein, ratFragile X Messenger Ribonucleoprotein 1

Identifiers

PMID38378836
PMCPMC10879511
OpenAlexW4391952863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.